The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Stryker's revenues will expand 4.1% and EPS will grow 10.0%.
The average estimate for revenue is $2.13 billion. On the bottom line, the average EPS estimate is $0.99.
Last quarter, Stryker notched revenue of $2.16 billion. GAAP reported sales were 7.2% higher than the prior-year quarter's $2.02 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.99. GAAP EPS of $0.91 for Q1 were 17% higher than the prior-year quarter's $0.78 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 67.8%, 70 basis points worse than the prior-year quarter. Operating margin was 24.1%, 20 basis points worse than the prior-year quarter. Net margin was 16.2%, 100 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $8.70 billion. The average EPS estimate is $4.11.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,441 members out of 1,473 rating the stock outperform, and 32 members rating it underperform. Among 425 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 415 give Stryker a green thumbs-up, and 10 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Stryker is outperform, with an average price target of $61.02.
- Add Stryker to My Watchlist.